LCTX has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
LCTX has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Lineage Cell Therapeutics's Free Cash Flow per Share for the three months ended in Dec. 2023 was $-0.04.
During the past 12 months, Lineage Cell Therapeutics's average Free Cash Flow per Share Growth Rate was -4325.00% per year. During the past 3 years, the average Free Cash Flow per Share Growth Rate was -8.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Free Cash Flow per Share growth rate.
During the past 13 years, the highest 3-Year average Free Cash Flow per Share Growth Rate of Lineage Cell Therapeutics was 53.00% per year. The lowest was -54.50% per year. And the median was -3.60% per year.
For the Biotechnology subindustry, Lineage Cell Therapeutics's 3-Year FCF Growth Rate, along with its competitors' market caps and 3-Year FCF Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Lineage Cell Therapeutics's 3-Year FCF Growth Rate distribution charts can be found below:
* The bar in red indicates where Lineage Cell Therapeutics's 3-Year FCF Growth Rate falls into.
This is the 3-year average growth rate of Free Cash Flow per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Free Cash Flow per Share growth rate.
Lineage Cell Therapeutics (AMEX:LCTX) 3-Year FCF Growth Rate Explanation
Free Cash Flow per Share is the amount of Free Cash Flow per outstanding share of the company's stock. Free Cash Flow is considered one of the most important parameters to measure a company's earnings power by value investors because it is not subject to estimates of Depreciation, Depletion and Amortization (DDA). However, when we look at the Free Cash Flow, we should look from a long term perspective, because any year's Free Cash Flow can be drastically affected by the spending on Property, Plant, & Equipment (PPE) of the business in that year. Over the long term, Free Cash Flow should give pretty good picture on the real earnings power of the company. It's used in the calculation of Forward Rate of Return (Yacktman) %.
Thank you for viewing the detailed overview of Lineage Cell Therapeutics's 3-Year FCF Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.
Anula Jayasuriya | director | 5150 EL CAMINO REAL, SUITE #A-32, LOS ALTOS CA 94022 |
Jill Ann Howe | officer: Chief Financial Officer | C/O DTX PHARMA, INC., 10655 SORRENTO VALLEY ROAD, SUITE 100, SAN DIEGO CA 92121 |
Dipti Amin | director | C/O LINEAGE CELL THERAPEUTICS, INC., 2173 SALK AVENUE, SUITE 200, CARLSBAD CA 92008 |
Brian M Culley | director, officer: President and CEO | 6725 MESA RIDGE ROAD, SUITE 100, SAN DIEGO CA 92121 |
Broadwood Partners Lp | 10 percent owner | BROADWOOD CAPITAL INC., 142 WEST 57TH STREET, 11TH FLOOR, NEW YORK NY 10019 |
Michael H. Mulroy | director | 1300 N. KELLOGG DRIVE, SUITE D, ANAHEIM CA 92807 |
Gary S. Hogge | officer: SVP,Clinical & Medical Affairs | 1010 ATLANTIC AVENUE, SUITE 102, ALAMEDA CA 94501 |
Samuel George A. Iii | officer: General Counsel/Secretary | C/O LINEAGE CELL THERAPEUTICS, INC., 2173 SALK AVENUE, SUITE 200, CARLSBAD CA 92008 |
Angus C. Russell | director | C/O INTERMUNE, INC., 3280 BAYSHORE BOULEVARD, BRISBANE CA 94005 |
Kevin Leon Cook | officer: Chief Financial Officer | C/O LINEAGE CELL THERAPEUTICS, INC., 2173 SALK AVENUE, SUITE 200, CARLSBAD CA 92008 |
Alexandra Hernandez | officer: Sr Director Finance/Controller | C/O LINEAGE CELL THERAPEUTICS, INC., 2173 SALK AVENUE, SUITE 200, CARLSBAD CA 92008 |
Brandi Roberts | officer: CFO & SVP, Finance | 12390 EL CAMINO REAL #150, SAN DIEGO CA 92130 |
Chase C. Leavitt | officer: General Counsel/Secretary | 1010 ATLANTIC AVENUE, SUITE 102, ALAMEDA CA 94501 |
Edward Wirth | officer: Chief Medical Officer | C/O INVIVO THERAPEUTICS HOLDING CORP., ONE BROADWAY, 14TH FLOOR, CAMBRIDGE MA 02142 |
Don M Bailey | director | 1300 N. KELLOGG DRIVE, SUITE D, ANAHEIM CA 92607 |
From GuruFocus
By Marketwired Marketwired • 02-26-2019
By Marketwired Marketwired • 01-04-2019
By Marketwired Marketwired • 01-30-2019
By GuruFocus Research GuruFocus Editor • 07-01-2021
By PRNewswire PRNewswire • 01-30-2019
By PRNewswire PRNewswire • 07-14-2022
By Marketwired Marketwired • 02-14-2019
By PRNewswire PRNewswire • 07-04-2022
By PRNewswire PRNewswire • 07-14-2022
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.